Marker Therapeutics receives $2.6 million FDA orphan‑products grant for pancreatic cancer Phase 1 study
Marker Therapeutics announced it was awarded a $2.6 million grant from the FDA’s Orphan Products Clinical Trials program to fund a Phase 1 trial of its MT‑601 multi‑antigen T‑cell therapy in locally advanced unresectable pancreatic cancer. The study is slated to start in the first quarter of 2027. The grant was one of six projects selected from 66 applications received in fiscal year 2026.
Why it matters
The non‑dilutive funding reduces the company’s cash‑burn needs while advancing a therapy that showed an 84.6% disease‑control rate in an earlier Phase 1/2 trial, potentially supporting future revenue and share‑price upside. The announcement lifted MRKR shares about 3.9% in pre‑market trading.
Key facts
- 1Marker Therapeutics was awarded a $2.6 million grant from the FDA’s Orphan Products Clinical Trials program. investing.com
- 2The grant will support a Phase 1 study of MT‑601 in patients with locally advanced unresectable pancreatic cancer. investing.com
- 3The pancreatic cancer study is expected to begin in the first quarter of 2027. investing.com
- 4Only six projects were funded from 66 applications received by the FDA in fiscal year 2026. tradingview.com
- 5Earlier Phase 1/2 data reported a disease‑control rate of 84.6% for MT‑601 combined with frontline chemotherapy. investing.com
- 6Pre‑market MRKR shares rose 3.87% to $1.08 following the grant announcement. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.